 <h1>Letermovir Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to letermovir: oral tablet</i></p><p>Other dosage forms:</p><ul><li>intravenous solution</li></ul><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, letermovir may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking letermovir:</p><p>
<i>More common</i>
</p><ul>
<li>Bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>rapid weight gain</li>
<li>tingling of the hands or feet</li>
<li>unusual weight gain or loss</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Dizziness</li>
<li>fainting</li>
<li>fast, pounding, or irregular heartbeat or pulse</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of letermovir may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Cough</li>
<li>diarrhea</li>
<li>headache</li>
<li>nausea</li>
<li>stomach pain</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to letermovir: intravenous solution, oral tablet</i></p><h3>General</h3><p>Side effects included those reported during treatment with study medication or within 2 weeks of study medication completion/discontinuation; the time for reporting side effects and laboratory abnormalities averaged about 22% longer with this drug compared to with placebo.  The side effects most commonly reported included nausea, diarrhea, vomiting, peripheral edema, cough, headache, fatigue, and abdominal pain.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Decreased hemoglobin (less than 6.5 g/dL: 2%; 6.5 to less than 8 g/dL: 14%; 8 to less than 9.5 g/dL: 41%), platelets (less than 25,000 cells/mcL: 27%; 25,000 to less than 50,000 cells/mcL: 17%; 50,000 to less than 100,000 cells/mcL: 20%), and absolute neutrophil count (less than 500 cells/mcL: 19%; 500 to less than 750 cells/mcL: 4%; 750 to less than 1000 cells/mcL: 8%) were reported during therapy or within 2 weeks of stopping therapy.</p><p><b>Very common</b> (10% or more): Decreased hemoglobin (up to 41%), decreased platelets (up to 27%), decreased absolute neutrophil count (up to 19%)</p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (27%), diarrhea (26%), vomiting (19%), abdominal pain (12%)</p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased serum creatinine (up to 17%)</p><p>Increased serum creatinine (greater than 2.5 mg/dL: 2%; greater than 1.5 to 2.5 mg/dL: 17%) was reported during therapy or within 2 weeks of stopping therapy.</p><h3>Other</h3><p><b>Very common</b> (10% or more): Peripheral edema (14%), fatigue (13%)</p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (14%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Dysgeusia, vertigo</p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (14%)</p>
<p><b>Frequency not reported</b>: Dyspnea</p><h3>Cardiovascular</h3><p>The cardiac side effect rate was higher in patients using this drug (13%) compared to those using placebo (6%).  Tachycardia (4% [compared to 2% with placebo]) and atrial fibrillation (3% [compared to 1% with placebo]) were the most commonly reported cardiac side effects.  Most cardiac side effects were reported as mild or moderate in severity.</p><p><b>Common</b> (1% to 10%): Tachycardia, atrial fibrillation</p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity reaction</p><p>After switching from the oral formulation, hypersensitivity reaction (associated with moderate dyspnea) was reported in 1 patient after the first IV infusion; as a result, treatment was discontinued.</p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Increased ALT, increased AST</p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Decreased appetite</p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Muscle spasms</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&amp;mid."  </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. "Product Information. Prevymis (letermovir)." Merck &amp; Company Inc, Whitehouse Station, NJ. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about letermovir</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>1 Review</li>
<li>Drug class: miscellaneous antivirals</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Letermovir &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Letermovir Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Prevymis</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>CMV Prophylaxis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to letermovir: intravenous solution, oral tablet</i></p><h3>General</h3><p>Side effects included those reported during treatment with study medication or within 2 weeks of study medication completion/discontinuation; the time for reporting side effects and laboratory abnormalities averaged about 22% longer with this drug compared to with placebo.  The side effects most commonly reported included nausea, diarrhea, vomiting, peripheral edema, cough, headache, fatigue, and abdominal pain.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Decreased hemoglobin (less than 6.5 g/dL: 2%; 6.5 to less than 8 g/dL: 14%; 8 to less than 9.5 g/dL: 41%), platelets (less than 25,000 cells/mcL: 27%; 25,000 to less than 50,000 cells/mcL: 17%; 50,000 to less than 100,000 cells/mcL: 20%), and absolute neutrophil count (less than 500 cells/mcL: 19%; 500 to less than 750 cells/mcL: 4%; 750 to less than 1000 cells/mcL: 8%) were reported during therapy or within 2 weeks of stopping therapy.</p><p><b>Very common</b> (10% or more): Decreased hemoglobin (up to 41%), decreased platelets (up to 27%), decreased absolute neutrophil count (up to 19%)</p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (27%), diarrhea (26%), vomiting (19%), abdominal pain (12%)</p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased serum creatinine (up to 17%)</p><p>Increased serum creatinine (greater than 2.5 mg/dL: 2%; greater than 1.5 to 2.5 mg/dL: 17%) was reported during therapy or within 2 weeks of stopping therapy.</p><h3>Other</h3><p><b>Very common</b> (10% or more): Peripheral edema (14%), fatigue (13%)</p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (14%)</p><p><b>Uncommon</b> (0.1% to 1%): Dysgeusia, vertigo</p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (14%)</p><p><b>Frequency not reported</b>: Dyspnea</p><h3>Cardiovascular</h3><p>The cardiac side effect rate was higher in patients using this drug (13%) compared to those using placebo (6%).  Tachycardia (4% [compared to 2% with placebo]) and atrial fibrillation (3% [compared to 1% with placebo]) were the most commonly reported cardiac side effects.  Most cardiac side effects were reported as mild or moderate in severity.</p><p><b>Common</b> (1% to 10%): Tachycardia, atrial fibrillation</p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity reaction</p><p>After switching from the oral formulation, hypersensitivity reaction (associated with moderate dyspnea) was reported in 1 patient after the first IV infusion; as a result, treatment was discontinued.</p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Increased ALT, increased AST</p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Decreased appetite</p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Muscle spasms</p><p id="ref_1">1. EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&amp;mid."  </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. "Product Information. Prevymis (letermovir)." Merck &amp; Company Inc, Whitehouse Station, NJ. </p><h2>More about letermovir</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>1 Review</li>
<li>Drug class: miscellaneous antivirals</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Letermovir &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Letermovir Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>CMV Prophylaxis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>